Results 121 to 130 of about 38,272 (314)

Use of sodium‐glucose cotransporter‐2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Clinical guidelines recommend sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) for individuals with type 2 diabetes mellitus (T2DM) and established or high risk of cardiorenal disease. This study examined real‐world SGLT2i use patterns among older adults with T2DM in British Columbia, Canada.
Hanin Harbi, Gregory Carney, Colin Dormuth, Jacob Volmer Stidsen, Iliana Lega, Lisa M. McCarthy, Guillaume Grenet, Anshula Ambasta, Raha Eskandari, Anton Pottegård, Wade Thompson   +10 more
wiley   +1 more source

Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials [PDF]

, 2016
Aims/hypothesis By analysing available evidence from randomised controlled trials (RCTs), we aimed to examine whether and to what extent sodium–glucose cotransporter 2 (SGLT2) inhibitors affect serum electrolyte levels in type 2 diabetes patients ...
Del Gobbo, Liana Christine, Li, Yufeng, Song, Yiqing, Tang, Huilin, Zhai, Suodi, Zhang, Jingjing, Zhang, Xi   +6 more
core   +3 more sources

#3763 RELATIONSHIP BETWEEN INITIAL EGFR DIP AND CHANGES IN LABORATORY PARAMETERS WITH DAPAGLIFLOZIN TREATMENT IN NON-DIABETIC CKD PATIENTS [PDF]

, 2023
Maiko Kokubu, Go Okanishi, Kosuke Tansho, Masaru Matsui   +3 more
openalex   +1 more source

Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause ...
Shifa Taj, Mohammed Zuber, Muhammed Rashid, Manik Chhabra, Krishna Undela, Smita Rawal, Lorenzo Villa Zapata   +6 more
wiley   +1 more source

Lack of Evidence for a Harmful Effect of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors on Fracture Risk among Type 2 Diabetes Patients: A Network and Cumulative Meta-Analysis of Randomized Controlled Trials [PDF]

, 2016
Aim To evaluate the comparative effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on risk of bone fracture in patients with type 2 diabetes mellitus (T2DM).
Hsu, Y. H., Li, D. D., Song, Y. Q., Tang, H. L., Wang, T. S., Zhai, S. D., Zhang, J. J.   +6 more
core   +2 more sources

Sex differences in trial representation and the cardiovascular effectiveness of newer glucose‐lowering agents in patients with and without type 2 diabetes: A systematic review and meta‐analysis of cardiovascular outcome trials

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The extent to which the cardiovascular benefits of sodium–glucose co‐transporter 2 inhibitors (SGLT‐2is) and glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) differ by sex remains unclear. This systematic meta‐analysis aimed to investigate sex differences in trial representation and the cardiovascular and kidney efficacy of SGLT‐2is ...
Magdaline Zawadka, Erwin Taguiam, Mê‐Linh Lê, Rohan Sanjanwala, Shuangbo Liu, Ashish H. Shah, Setor K. Kunutsor   +6 more
wiley   +1 more source

Dapagliflozin Improves Angiogenesis after Hindlimb Ischemia through the PI3K-Akt-eNOS Pathway

Biomolecules
Recently, the vascular protective effect of anti-diabetic agents has been receiving much attention. Sodium glucose cotransporter 2 (SGLT2) inhibitors had demonstrated reductions in cardiovascular (CV) events.
Li Han, Guoxin Ye, Wenjing Su, Yuankang Zhu, Wenqi Wu, Liangshi Hao, Jing Gao, Zhen Li, Fang Liu, Junli Duan   +9 more
doaj   +1 more source

Additional therapy with dapagliflozin in patients with type 2 diabetes who have in adequate glycemin control [PDF]

, 2015
Study objectives: to assess the efficacy of dapagliflozin in patients with poorly controlled type 2 diabetes receiving metformin and ...
Ejire, J.
core  

SGLT inhibitor adjunct therapy in type 1 diabetes [PDF]

, 2018
Non-insulin adjunct therapies in type 1 diabetes have been proposed as a means of improving glycaemic control and reducing risk of hypoglycaemia. Evidence to support this approach is, however, scant and few pharmacological agents have proved effective ...
AT Sands, B Neal, BA Perkins, C Beall, C Mathieu, Diabetes Control and Complications Trial Research Group, DM Nathan, DM Nathan, DR Powell, DZ Cherney, E Ferrannini, G Luippold, JA McKnight, JB Buse, JR Petrie, KJ Griffin, KM Miller, KM Thrailkill, KV Hari Kumar, L Govan, NS Patel, P Dandona, P George, Robert R. Henry, Rory J. McCrimmon, RR Henry, RR Henry, S Edelman, S Vella, SJ Livingstone, SJ Livingstone, SK Garg, SK Garg, T Danne, The DCCT Research Group, TR Pieber, Y Zhao   +36 more
core   +2 more sources

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors.
Hisashi Makino, Masato Kasahara, Ryuzo Takashima, Shu Kasama, Naoki Ozu, Hyohun Park, Qingxing Chen, Kazuhiko Tsuruya, Mayu Tochiya, Yoko Omura‐Ohata, Tamiko Tamanaha, Michio Noguchi, Takeshi Aiba, Fumiki Yoshihara, Kiminori Hosoda   +14 more
wiley   +1 more source